NEWS
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Altamira Therapeutics (Nasdaq:CYTO) has announced the publication of a preclinical study demonstrating effective treatment of abdominal aortic aneurysm (AAA) using their SemaPhore™ nanoparticles to deliver SOD2 mRNA. The study, conducted by researchers from Washington University and the University of South Florida, showed significant reduction in aorta dilation p<0.01) compared to untreated controls in an AAA mouse model.
The treatment approach targets oxidative stress by boosting mitochondrial SOD2 expression, reducing levels of reactive oxygen species (ROS). This nanotherapeutic mRNA delivery method may have potential applications in managing small AAAs and preventing ruptures, which are often life-threatening.
The treatment approach targets oxidative stress by boosting mitochondrial SOD2 expression, reducing levels of reactive oxygen species (ROS). This nanotherapeutic mRNA delivery method may have potential applications in managing small AAAs and preventing ruptures, which are often life-threatening.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7386Visitors
Follow